Spontaneous bacterial peritonitis (SBP) is a common and severe complication in patients with cirrhosis and ascites [1] . SBP occurs in 10%-25% of patients with liver cirrhosis with ascites, with a mortality rate ranging from 20% to 40% [2] [3] [4] [5] . Empirical antibiotic therapy should be initiated immediately after the diagnosis of SBP is made, without prior knowledge of the causative organisms and their in vitro susceptibility. Because gram-negative aerobic bacteria from the Enterobacteriaceae family are the most common causative organisms, the initial empirical antibiotic therapy of SBP should cover these organisms [6, 7] . Cefotaxime has been considered the first choice of empirical antibiotics in SBP treatment, along with other broad-spectrum cephalosporins or amoxicillin-clavulanate [6, [8] [9] [10] .
Most cirrhotic patients have a high risk of nosocomial infection, because they undergo frequent hospitalization and experience long hospital stays [11] . Previous reports have focused on all types of SBP or only community-acquired infections [12] . Recent studies that included patients with nosocomial SBP have demonstrated that nosocomial pathogens are more resistant to antibiotics, compared with pathogens acquired in the community [13, 14] . However, few data are available regarding clinical and microbiological characteristics of nosocomial versus community-acquired SBP during this era of increasing rates of antimicrobial resistance. Furthermore, a previous study regarding the influence of nosocomial acquisition on the clinical outcomes of patients with SBP did not show a significant difference between outcomes for community-acquired SBP and those for nosocomial SBP [14] .
In the present study, we delineated the differences in clinical and microbiological characteristics between nosocomial and community-acquired SBP. This study was performed to identify the risk factors for mortality and evaluate the impact of nosocomial acquisition on outcome in cirrhotic patients with SBP.
MATERIALS AND METHODS
Study design and population. A retrospective, observational cohort study was conducted to evaluate the outcomes of cirrhotic patients with SBP and to determine the impact of nosocomial acquisition on clinical outcome. We compared data from patients with nosocomial infection with data from those with community-acquired infection. Microbiology laboratory files were reviewed to identify all cases with a positive result of an ascitic fluid culture among patients hospitalized at the Samsung Medical Center (Seoul, Republic of Korea) during the period from 1 January 2000 through 31 June 2007. Only patients aged 115 years with liver cirrhosis were included, and only 1 episode for each patient was included in the analysis.
Patients with a culture positive for skin contaminants (i.e., coagulase-negative staphylococci or Corynebacterium, Propionibacterium, or Bacillus species) and those with secondary peritonitis were excluded from the study. Secondary peritonitis was considered in cases of polymicrobial infection. We reviewed the medical records of the patients, and the following information was collected from patients: age, sex, cause of cirrhosis, ChildPugh score, concomitant hepatocellular carcinoma, initial symptoms at the time of presentation, gastrointestinal bleeding, presentation with septic shock, laboratory results, previous SBP history, and empirical antibiotic regimen. The primary outcome measure was 30-day mortality rate. 
Definitions. SBP was defined by an ascitic fluid polymorphonuclear leukocyte count у250 cells/mm 3 and a positive culture result. Nosocomial infection was defined as an infection that occurred 172 h after admission to the hospital, and the infections diagnosed within the first 72 h of hospitalization were classified as community-acquired infection. Septic shock was defined as sepsis associated with evidence of organ hypoperfusion and a systolic blood pressure !90 mm Hg or 130 mm Hg less than the baseline or a requirement for the use of a vasopressor to maintain the blood pressure. The initial empirical antimicrobial therapy was considered appropriate if the initial antibiotics, which were administered within 24 h of acquisition of ascitic fluid samples, included at least 1 antibiotic that was active in vitro against the isolated pathogen and if the dosage and route of administration conformed to current medical standards. We considered antimicrobial therapy to be inappropriate if the drugs used did not have in vitro activity against the isolate or if the patient did not receive antimicrobial therapy.
Laboratory testing. During the study period, ascitic fluid specimens were obtained aseptically by paracentesis and inoculated into blood culture bottles at the bedside. Ascitic fluid samples were also sent to the microbiology laboratory for polymorphonuclear leukocyte counting and Gram staining. The recovery of isolates from ascitic fluid was performed with the BACTEC model 9240 system (BD Diagnostic Instrument Systems) or the BacT/ALERT 3D system (bioMérieux). Identification of isolates was performed using a standard identification card. Antibiotic susceptibility testing of isolates was performed on the VITEK II automated system (bioMérieux) using the modified broth microdilution method. MIC breakpoints and quality-control protocols were used according to standards established by the Clinical and Laboratory Standards Institute [15] .
Statistical analysis. Student's t test was used to compare continuous variables, and the x 2 test or Fisher's exact test was used to compare categorical variables. In identifying the risk factors for mortality, proportional hazards Cox regression model was used to control for the effects of confounding variables. Variables with in the univariate analyses were P ! .05 candidates for multivariate analysis. In addition, in identifying the risk factors for resistance to third-generation cephalosporins, stepwise logistic regression was used. We used backward elimination of any variable that did not contribute to the model on the grounds of the likelihood ratio test, using a statistical significance cutoff of .05. All P values were 2-tailed, and P values (table 1) . However, the Child-Pugh score was statistically significantly higher in patients with nosocomial SBP than in those with community-acquired SBP, and the receipt of inappropriate initial antibiotics and prior gastrointestinal bleeding history р7 days after illness onset were statistically significantly more common among patients with nosocomial SBP than among those with community-acquired SBP.
RESULTS

Clinical characteristics of patients with nosocomial versus
Microbiological characteristics of nosocomial versus community-acquired SBP. The organisms isolated from the ascitic fluid of patients with SBP are listed in ). Of 236 pa-P p .001 tients, 234 received empirical antimicrobial therapy: 186 (79.5%) received third-generation cephalosporins, 20 (8.5%) received fluoroquinolones, 18 (7.7%) received carbapenems, and 6 (2.6%) received b-lactam/b-lactamase inhibitors. Multivariate analysis using a proportional hazards Cox regression model, including the variables associated with mortality by univariate analysis, showed that the significant independent risk factors for mortality were concomitant hepatocellular carcinoma, nosocomial infection, presentation with acute renal failure or septic shock, and inappropriate initial antimicrobial therapy (table 3) .
Predictors of mortality in patients with SBP caused by gram-negative organisms. Gram-negative bacilli accounted for 72% of isolated pathogens in SBP, and we thus tried to identify the predictors of mortality in SBP caused by gramnegative bacilli. Factors associated with 30-day mortality rate are given in table 4. In the multivariate analysis, Child-Pugh class C, concomitant hepatocellular carcinoma, presentation with acute renal failure or septic shock, and inappropriate initial therapy were found to be independent factors associated with 30-day mortality ( ) (model 1 in table 4). When inap-P ! .05 propriate antimicrobial therapy was excluded in the propor- tional hazards Cox regression models, third-generation cephalosporin resistance was found to be an independent factor associated with 30-day mortality ( ) (model 2 in table 4).
The survival curve also shows that patients with third-generation cephalosporin-resistant SBP had a significantly lower probability of survival than did patients with third-generation cephalosporin-susceptible SBP ( ) ( figure 1 ). P p .023 Prior use of antibiotics, nosocomial acquisition of pathogens, and presentation with acute renal failure or septic shock occurred more frequently among patients with third-generation cephalosporin-resistant SBP than among patients with third-generation cephalosporin-susceptible SBP (table 5) . Multivariate analysis showed that previous use of third-generation cephalosporins, nosocomial acquisition of pathogens, and presentation with acute renal failure were independent factors associated with third-generation cephalosporin resistance (table 5) .
DISCUSSION
In the present study, we described the clinical and microbiological characteristics of nosocomial versus community-acquired SBP. To our knowledge, this is the largest study to have compared the clinical characteristics and outcomes of patients with nosocomial SBP with those of patients with communityacquired SBP.
Nosocomial infections are associated with the emergence of drug-resistant bacteria in a broad spectrum of pathological conditions; however, little is known about nosocomial SBP in cirrhotic patients [11] . In a previous study, Bert et al. [13] observed that nosocomial SBP isolates were significantly more resistant to antibiotics than community-acquired isolates. However, the treatment outcome of nosocomial SBP (10-day mortality rate) was not significantly different from communityacquired SBP. In contrast, our results showed that nosocomial acquisition affected adversely the outcome of SBP. Nosocomial infection was strongly associated with mortality in our multivariate analysis, even after adjustments were made for underlying illness and other confounding variables. Our data suggest that the acquisition site of infection (i.e., nosocomial infection) may influence the outcome of patients with SBP and that a new therapeutic strategy is needed for the management of nosocomial SBP.
Because the underlying illnesses in nosocomial SBP were more severe (as determined by Child-Pugh score) than in community-acquired SBP, it may be presumed that nosocomial SBP may have a worse prognosis because of the greater severity of underlying illness. However, after adjusting for other prognostic factors associated with mortality, nosocomial SBP was still identified as an independent risk factor for mortality in this study. Not surprisingly, the severity of underlying illness and initial inappropriate antibiotic therapy were also prognostic factors of mortality.
Third-generation cephalosporins, such as cefotaxime, were the most frequently prescribed antibiotics for empirical therapy, regardless of the source of infection acquisition in our study. Consequently, 40.5% of patients with nosocomial SBP received inappropriate initial antimicrobial therapy, and most of them had SBP caused by antimicrobial-resistant gram-negative bacilli. Third-generation cephalosporin resistance was associated with previous use of antibiotics within 90 days and nosocomial infection. Our results suggest that third-generation cephalosporins may not be the optimal choice for the first-line treatment of nosocomial SBP, especially in populations with a high prevalence of gram-negative bacilli with resistance to thirdgeneration cephalosporins. These results correspond with the results of a recent study, which reported that initial treatment with cefotaxime failed more frequently than expected, and an increase in health care-related infections with antibiotic-resistant pathogens may explain this finding [16] .
Our study has some limitations. First, it was observational, and thus unknown risk factors for mortality might have been unequally distributed between the 2 groups. Second, patients with bacteria ascites (defined by a positive ascitic fluid culture result without an increased polymorphonuclear leukocyte count) or culture-negative neutrocytic ascites (defined by an ascitic fluid polymorphonuclear leukocyte count у250 cells/ mm 3 and a negative culture result) were not included in this study. Patients with these conditions are sometimes treated with antibiotics in clinical practice; thus, selection bias may have occurred, because we only included patients with cultureproven SBP in this study. For example, our study showed that fever was more common in patients with nosocomial SBP and abdominal pain was more common in patients with community-acquired SBP. It is unlikely that the initial presenting symptoms of patients with nosocomial SBP were different from those of patients with community-acquired SBP. Thus, those findings could be explained in part by selection bias. Finally, our study was performed at a single, large institution, and the results may or may not be applicable to other hospitals.
In conclusion, nosocomial SBP, which is more frequently caused by antibiotic-resistant organisms, has a poorer outcome than community-acquired SBP. Nosocomial acquisition was found to be significantly associated with higher mortality rates, along with inappropriate initial antimicrobial therapy and third-generation cephalosporin resistance. Third-generation cephalosporin may not be appropriate for the empirical treatment of SBP in cirrhotic patients with an increased risk of resistant isolates, particularly in patients with nosocomial SBP.
